Skip to main content
Figure 1 | Vascular Cell

Figure 1

From: Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia

Figure 1

(A) Effect of rapamycin, imatinib or combination of imatinib and rapamycin on tsc2ang1 cell line proliferation. Cells were treated with vehicle control (DMSO), rapamycin (5nM), imatinib (10 μM) or imatinib (10 μM) + rapamycin (5nM) (shown along X-axis) for 24 h and counted using a Coulter counter. Treatment at each concentration was performed in triplicate. The Y-axis represents cell number. (B) Downregulation of Phospho-PDGFR-β by combinational treatment; Tsc2ang1 cells were treated with DMSO, rapamycin5nM, imatinib10uM or rapamycin5nM + imatinib10uM for 24 hours prior to harvest. Combination rapamycin + imatinib treatment inhibits the levels of phospho- PDGFR-β (Tyr 1021).

Back to article page